FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387002247> ?p ?o ?g. }

• W4387002247 endingPage "398" @default.
• W4387002247 startingPage "387" @default.
• W4387002247 abstract "ABSTRACTIntroduction In the treatment scenario of PanNETs-targeted therapies are desired but limited, as rarity and heterogeneity on PanNETs pose limitations to their development.Areas covered We performed a literature review searching for promising druggable biomarkers and potential treatments to be implemented in the next future. We focused on treatments which have already reached clinical experimentation, although in early phases. Six targets were identified, namely Hsp90, HIFa, HDACs, CDKs, uPAR, and DDR. Even though biological rational is strong, so far reported efficacy outcomes are quite disappointing. The reason of that should be searched in the patients’ heterogeneity, lack of biomarker selection, poor knowledge of interfering mechanisms as well as difficulties in patients accrual. Moreover, different ways to assess treatment efficacy should be considered, other than response rate, in light of the more indolent nature of NETs.Expert opinion Development of targeted treatments in PanNETs is still an uncovered area, far behind other more frequent cancers. Rarity of NETs led to accrual of unselected populations, possibly jeopardizing the drug efficacy. Better patients’ selection, both in terms of topography, grading and biomarkers is crucial and will help understanding which role targeted therapies can really play in these tumors.KEYWORDS: NETsNENsPanNETstarget therapyHsp90HIFaVHLHDAC Article highlights PanNETs incidence has been gradually increasing over the last two decades and still represents a clinical challenge for physiciansIn the modern oncology era, tailored treatments for PanNETs are limited and no biomarker-guided therapy has ever been approved, despite EVE and SUN being considered targeted agents to some extentStrong rationale and preclinical evidence have drawn attention to potential biomarkers to be targeted in the next future, among which we selected the most promising targets: Hsp, HDAC, CDK, HIF, DDR, uPARKey limitations in biomarker-guided therapies development are represented by lack of biomarker stratification, different primary sites inclusion and previous treatments, as well as inadequate endpoint selectionTargeted agents may influence other treatment efficacy and possibly synergize with them. Therefore, even though biomarker-guided monotherapy may appear unsatisfactory, they may still play a role in combination with other drugs, to enhance their efficacy and overcome primary and secondary resistanceDeclaration of interestN Fazio reports having received from AAA (Advisory board and invited speaker), Novartis (Advisory board), Hutchmed (Advisory board), Merck (Advisory board and invited speaker), and MSD (Advisory board), having received research grants AAA, Merck and Ipsen, having served as local PI of clinical trials for 4SC, Astellas, Beigene, Fibrogen, Incyte, and Ipsen, having served as internal reviewer of NET guidelines for AIOM, having served as a member of the executive committee of ENETS, having served as member of NET faculty of ESMO, and having served as member of the steering committee of SPARC Europe.The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis paper was not funded." @default.
• W4387002247 created "2023-09-26" @default.
• W4387002247 creator A5014888732 @default.
• W4387002247 creator A5020435379 @default.
• W4387002247 creator A5031081717 @default.
• W4387002247 creator A5038896664 @default.
• W4387002247 creator A5047539709 @default.
• W4387002247 creator A5056705554 @default.
• W4387002247 creator A5062592912 @default.
• W4387002247 creator A5065459543 @default.
• W4387002247 creator A5070805535 @default.
• W4387002247 creator A5078823780 @default.
• W4387002247 creator A5082304162 @default.
• W4387002247 creator A5083277135 @default.
• W4387002247 date "2023-09-03" @default.
• W4387002247 modified "2023-09-29" @default.
• W4387002247 title "Promising targetable biomarkers in pancreatic neuroendocrine tumours" @default.
• W4387002247 cites W1892562842 @default.
• W4387002247 cites W1977999028 @default.
• W4387002247 cites W1980451534 @default.
• W4387002247 cites W2008074714 @default.
• W4387002247 cites W2017082986 @default.
• W4387002247 cites W2022531767 @default.
• W4387002247 cites W2026888844 @default.
• W4387002247 cites W2033106731 @default.
• W4387002247 cites W2046624103 @default.
• W4387002247 cites W2057103712 @default.
• W4387002247 cites W2089353165 @default.
• W4387002247 cites W2090232354 @default.
• W4387002247 cites W2106821496 @default.
• W4387002247 cites W2115686439 @default.
• W4387002247 cites W2124584525 @default.
• W4387002247 cites W2127931911 @default.
• W4387002247 cites W2131733445 @default.
• W4387002247 cites W2135049144 @default.
• W4387002247 cites W2146222370 @default.
• W4387002247 cites W2154495827 @default.
• W4387002247 cites W2156804775 @default.
• W4387002247 cites W2157174734 @default.
• W4387002247 cites W2158474413 @default.
• W4387002247 cites W2158476626 @default.
• W4387002247 cites W2162343852 @default.
• W4387002247 cites W2232569012 @default.
• W4387002247 cites W2261891160 @default.
• W4387002247 cites W2408937349 @default.
• W4387002247 cites W2409400193 @default.
• W4387002247 cites W2514976083 @default.
• W4387002247 cites W2588295537 @default.
• W4387002247 cites W2589112207 @default.
• W4387002247 cites W2590266319 @default.
• W4387002247 cites W2590284380 @default.
• W4387002247 cites W2596205188 @default.
• W4387002247 cites W2607151521 @default.
• W4387002247 cites W2616420862 @default.
• W4387002247 cites W2761209998 @default.
• W4387002247 cites W2774407145 @default.
• W4387002247 cites W2790555529 @default.
• W4387002247 cites W2792897966 @default.
• W4387002247 cites W2796335748 @default.
• W4387002247 cites W2884314425 @default.
• W4387002247 cites W2891140245 @default.
• W4387002247 cites W2897595861 @default.
• W4387002247 cites W2898088739 @default.
• W4387002247 cites W2910591767 @default.
• W4387002247 cites W2913257972 @default.
• W4387002247 cites W2975888204 @default.
• W4387002247 cites W2978807231 @default.
• W4387002247 cites W2994628711 @default.
• W4387002247 cites W3005666666 @default.
• W4387002247 cites W3007442940 @default.
• W4387002247 cites W3020286464 @default.
• W4387002247 cites W3026325254 @default.
• W4387002247 cites W3032602566 @default.
• W4387002247 cites W3036666213 @default.
• W4387002247 cites W3080682266 @default.
• W4387002247 cites W3083599586 @default.
• W4387002247 cites W3084114043 @default.
• W4387002247 cites W3091397028 @default.
• W4387002247 cites W3092300223 @default.
• W4387002247 cites W3093539240 @default.
• W4387002247 cites W3097597947 @default.
• W4387002247 cites W3114639232 @default.
• W4387002247 cites W3121071854 @default.
• W4387002247 cites W3147705470 @default.
• W4387002247 cites W3155273322 @default.
• W4387002247 cites W3156669433 @default.
• W4387002247 cites W3168444467 @default.
• W4387002247 cites W3177983648 @default.
• W4387002247 cites W3186500591 @default.
• W4387002247 cites W3213347188 @default.
• W4387002247 cites W3215251371 @default.
• W4387002247 cites W4205148977 @default.
• W4387002247 cites W4205777536 @default.
• W4387002247 cites W4206978367 @default.
• W4387002247 cites W4210795875 @default.
• W4387002247 cites W4213052925 @default.
• W4387002247 cites W4213287068 @default.
• W4387002247 cites W4214882242 @default.

• next